Literature DB >> 15985750

Genetic disorders of surfactant homeostasis.

Jeffrey A Whitsett1, Susan E Wert, Yan Xu.   

Abstract

Adaptation to air breathing at birth requires the precise orchestration of cellular processes to initiate fluid clearance, enhance pulmonary blood flow, and to synthesize and secrete pulmonary surfactant needed to reduce surface tension at the air-liquid interface in the alveoli. Genetic programs regulating the synthesis of the surfactant proteins and lipids required for the production and function of pulmonary surfactant are highly conserved across vertebrates, and include proteins that regulate the synthesis and packaging of pulmonary surfactant proteins and lipids. Surfactant proteins B and C (SP-B and -C) are small, uniquely hydrophobic proteins that play important roles in the stability and spreading of surfactant lipids in the alveolus. Deletion or mutations in SP-B and -C cause acute and chronic lung disease in neonates and infants. SP-B and -C are synthesized and packaged with surfactant phospholipids in lamellar bodies. Normal lamellar body formation requires SP-B and a member of the ATP-binding cassette (ABC) family of ATP-dependent membrane-associated transport proteins, ABCA3. Mutations in ABCA3 cause fatal respiratory disease in newborns and severe chronic lung disease in infancy. Expression of SP-B, -C, and ABCA3 are coregulated during late gestation by transcriptional programs influenced by thyroid transcription factor-1 and forkhead box a2, transcription factors that regulate both differentiation of the respiratory epithelium and transcription of genes required for perinatal adaptation to air breathing. Copyright 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985750     DOI: 10.1159/000084875

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  7 in total

1.  Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children.

Authors:  Florence Flamein; Laure Riffault; Céline Muselet-Charlier; Julie Pernelle; Delphine Feldmann; Laurence Jonard; Anne-Marie Durand-Schneider; Aurore Coulomb; Michèle Maurice; Lawrence M Nogee; Nobuya Inagaki; Serge Amselem; Jean Christophe Dubus; Virginie Rigourd; François Brémont; Christophe Marguet; Jacques Brouard; Jacques de Blic; Annick Clement; Ralph Epaud; Loïc Guillot
Journal:  Hum Mol Genet       Date:  2011-11-07       Impact factor: 6.150

Review 2.  An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy.

Authors:  Geoffrey Kurland; Robin R Deterding; James S Hagood; Lisa R Young; Alan S Brody; Robert G Castile; Sharon Dell; Leland L Fan; Aaron Hamvas; Bettina C Hilman; Claire Langston; Lawrence M Nogee; Gregory J Redding
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

Review 3.  Genetic disorders of surfactant dysfunction.

Authors:  Susan E Wert; Jeffrey A Whitsett; Lawrence M Nogee
Journal:  Pediatr Dev Pathol       Date:  2009 Jul-Aug

4.  Effects of palmitoylation on dynamics and phospholipid-bilayer-perturbing properties of the N-terminal segment of pulmonary surfactant protein SP-C as shown by 2H-NMR.

Authors:  Azucena Gonzalez-Horta; David Andreu; Michael R Morrow; Jesús Perez-Gil
Journal:  Biophys J       Date:  2008-05-23       Impact factor: 4.033

5.  rtTA toxicity limits the usefulness of the SP-C-rtTA transgenic mouse.

Authors:  Mitsuru Morimoto; Raphael Kopan
Journal:  Dev Biol       Date:  2008-11-01       Impact factor: 3.582

6.  A systems approach to mapping transcriptional networks controlling surfactant homeostasis.

Authors:  Yan Xu; Minlu Zhang; Yanhua Wang; Pooja Kadambi; Vrushank Dave; Long J Lu; Jeffrey A Whitsett
Journal:  BMC Genomics       Date:  2010-07-26       Impact factor: 3.969

7.  Secretoglobin 3A2 Exhibits Anti-Fibrotic Activity in Bleomycin-Induced Pulmonary Fibrosis Model Mice.

Authors:  Yan Cai; Shioko Kimura
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.